IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update

13 On Treatment Predose IDE397 Clinical Phase 1 Interim Tumor Pharmacodynamic Data Exposure-Dependent Tumor SDMA Reduction Observed in Target Tumor Types Cohort 3: Pancreatic Cancer <5% Reduction of Tumor SDMA Tumor SDMA IHC, 20X Cohort 4: Pancreatic Cancer 100% Reduction of Cytoplasmic Tumor SDMA 12% Reduction of Nuclear Tumor SDMA Tumor SDMA IHC, 20X Cohort 5: NSCLC 95% Reduction of Tumor SDMA Tumor SDMA IHC, 20X AUC = 1.0 x 'SS IDEAYA Data: % Reduction of Tumor SDMA measured by IHC H-Score 1 AUC ss values normalized to Cohort 3 value On Treatment Predose AUC SS = 2.4 x On Treatment Predose AUC S₁ = 5.9 x SS gsk IDEA A BIOSCIENCES

View entire presentation